|Year : 2018 | Volume
| Issue : 2 | Page : 147-154
|Conventional versus giant basal cell carcinoma, a review of 57 Cases: Histologic differences contributing to excessive growth
J Chase Purnell1, Jerad M Gardner2, J Ahmad Brown3, Sara C Shalin2
1 Department of Dermatology, University of Alabama, Birmingham, AL, USA
2 Department of Pathology and Dermatology, University of Arkansas for Medical Sciences, Little Rock, USA
3 Arkansas Dermatopathology PLLC, Little Rock, AR, USA
|Date of Web Publication||6-Apr-2018|
Dr. Sara C Shalin
Department of Pathology, University of Arkansas For Medical Sciences, 4301 W. Markham, Slot 517, Little Rock, AR 72205
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Giant basal cell carcinoma (GBCC) is defined as a basal cell carcinoma (BCC) exceeding 5 cm in size. While these tumors impart significant morbidity due to local tissue destruction and have a higher rate of metastatic disease than their conventional (smaller) counterparts, reasons for their large size remain unclear. While theories relating to neglect or faster growth rate are often invoked; to date, there has not been a comprehensive evaluation of the histologic features of these large tumors that may contribute to their size. Methods: Histologic features of GBCCs (n = 29) were evaluated and compared to those of conventional BCC (n = 28). Available clinical demographic data were also reviewed. Results: GBCCs, in addition to overall larger size, more often were thicker, displayed ulceration, and showed a more infiltrative growth pattern than their conventional counterparts. These rare tumors also displayed an insignificant increased propensity for a brisk host immune response, and the infiltrate significantly more often included clusters of plasma cells. Conclusions: Most histologic features seen in GBCCs likely reflect their large size. Histologic features alone are unlikely to explain the size of these rare tumors. The possibility of an altered host immune response contributing to the growth of these tumors requires further investigation.
Keywords: Basal cell carcinoma, giant basal cell carcinoma, host immune response, plasma cells
|How to cite this article:|
Purnell J C, Gardner JM, Brown J A, Shalin SC. Conventional versus giant basal cell carcinoma, a review of 57 Cases: Histologic differences contributing to excessive growth. Indian J Dermatol 2018;63:147-54
|How to cite this URL:|
Purnell J C, Gardner JM, Brown J A, Shalin SC. Conventional versus giant basal cell carcinoma, a review of 57 Cases: Histologic differences contributing to excessive growth. Indian J Dermatol [serial online] 2018 [cited 2022 May 18];63:147-54. Available from: https://www.e-ijd.org/text.asp?2018/63/2/147/229442
What was known?
- Giant basal cell carcinomas are >5 cm in diameter and can impose significant morbidity.
| Introduction|| |
The most common cutaneous malignancy seen around the world in fair complected populations is basal cell carcinoma (BCC), outnumbering squamous cell carcinoma by 4:1.,, While they may be locally invasive and destructive, this tumor rarely metastasize and surgery most often is curative. BCC is generally classified into subtypes determined by histopathologic growth pattern and designed to indicate their propensity for aggressive behavior. Superficial and nodular subtypes indicate relatively indolent behavior, while micronodular and infiltrative/morpheaform subtypes correspond to more locally aggressive behavior.,,,, This study focuses on giant BCC (GBCC), which can comprise any of the above-mentioned histopathologic subtypes and is currently classified by size alone (>5 cm in greatest dimension).
While comprising <0.5% of all BCCs, morbidity imposed by GBCC can be substantial., The cause for excessive growth in GBCC is unknown; existing theories invoke patient characteristics, characteristics of the tumor, or its microenvironment. Neglect, denial, and inability/unwillingness to seek treatment, weakened immunity, and oncogenic viruses have all been suggested as reasons for the large size of GBCC.,,,, Some literatures suggest that larger BCC may grow at a faster rate than conventional BCC., While studies examining the clinical characteristics of these rare tumors exist,, large case series specifically investigating the histopathologic features of GBCC are lacking in the current literature. It is unknown whether GBCCs possess unique histological features that could contribute to their large size and potentially faster growth rate. We hypothesized that GBCC may possess unique histopathologic characteristics compared to conventional BCC that could explain their large size, and we evaluated histopathologic characteristics of these tumors.
| Materials and Methods|| |
After Institutional Review Board approval, histology slides and blocks were retrieved from the pathology department of our institution in the central United States and from a local private dermatopathology practice. GBCCs were identified by searching pathology reports where either (1) clinical tumor size was mentioned in accompanying clinical information or corresponding clinical note in the electronic medical record or (2) gross description and/or final diagnosis described tumor size >5.0 cm. In total, 29 GBCCs were retrieved, both biopsies and excisions. A control group of samples (n = 28) comprised of a similar number of biopsies and excisions, based on the evaluation of surgical pathology reports documenting tumor size (within clinical information, gross description, or final diagnosis) as <5.0 cm. Recurrent tumors were excluded. For both groups, if the case consisted of multiple blocks with tumor, all slides from the case were blindly reviewed by one pathologist (S. C. S.), but a representative slide documenting the deepest area of invasion was chosen for inclusion in the study and reviewed by all study authors. Once retrieved, the slides were randomized. Appropriate demographic data were recorded from pathology reports including patient sex, age, tumor site, and size. Duration of tumor growth was generally not included on reviewed pathology reports, and our study was not designed to collect this information from the clinical records. Similarly, Fitzpatrick skin type was generally not included on reviewed pathology reports; however, as this study was conducted in the central United States, it can be safely presumed that the majority (if not all) of the patients in this study were fair-skinned Caucasians. All authors (including board-certified dermatopathologists S. C. S, J. M. G, and J. A. B) examined and recorded histopathologic characteristics of each tumor blinded to tumor size. The following characteristics were recorded: subtype (nodular, infiltrative, or superficial), tumor thickness/depth of invasion, perineural or lymphovascular invasion, host inflammation components, mitoses per mm 2, necrosis, significant squamous or adnexal differentiation, tumor cell pleomorphism, calcification, and ulceration. Any other concurrent diagnoses were also noted. Tumor thickness/depth of invasion was measured as for melanoma, assessed in millimeters by measuring from granular layer of the epidermis to the deepest extent of dermal involvement by tumor. When granular layer was not present due to ulceration, measurement was made from the base of the ulcer to the deepest extent of dermal involvement. Host inflammation was graded as low (absent, minimal, or nonbrisk) and high (brisk infiltrate consistently associated with majority of tumor nests). Presence or absence of plasma cell (PC) aggregates was also recorded. Results were recorded, analyzed, and statistical analyses were applied when appropriate. All statistics and calculations were performed using automated calculations for Fisher's exact test, Chi-square test, and Student's t-test, provided by GraphPad software (http://graphpad.com/quickcalcs, GraphPad Software, La Jolla, CA, USA).
| Results|| |
A total of 57 patient samples were obtained for analysis in this study, comprising 28 conventional BCCs and 29 GBCCs. Gender distribution in the conventional BCC group was 28.6% females (8/28) and 71.4% males (20/28), while proportions in the GBCC group were 17.2% females (5/29) and 82.7% males (24/29) (P = 0.36). Ages of patients diagnosed with BCC ranged from 40 to 87 years, with a mean of 66.5 ± 11.76 years, similar to ages of patients in the GBCC group, which ranged from 28 to 89 years, with a mean of 66.93 ± 15.74 years (P = 0.90). Specimen types (biopsies and excisions) were equally represented in both groups, with biopsies representing 13/28 and 13/29 of BCC and GBCC groups, respectively (P = 1.0). Anatomic site of tumors was also similar between groups. In the conventional BCC group, 60.7% of tumors (17/28) were located on the head and neck, 25% (7/28) on the trunk, and 14.3% (4/28) on the extremities. Similarly, in the GBCC group, 55.2% of tumors (16/29) were located on the head and neck, 27.6% (8/29) on the trunk, and 17.2% (5/29) on the extremities. Demographic information for the two groups is provided in [Table 1].
|Table 1: Clinical and demographic information of giant versus conventional basal cell carcinoma|
Click here to view
Histologic features of the tumors are recorded in [Table 2]. As expected, average tumor size, as determined by the greatest single dimension recorded, differed significantly between groups: average size of GBCC was 6.96 cm and was 1.54 cm for conventional BCC (P < 0.001). Average depth of invasion was significantly greater in GBCC, with conventional BCC group ranging from 0.25 mm to 10 mm (average: 3.14 mm, standard deviation [SD]: 2.7 mm) but with GBCC group ranging from 0.35 mm to 23 mm (average: 5.83 mm, SD: 5.75) (P = 0.03). Ulceration was present significantly more often in GBCC, with 22 of 29 tumors (75.9%) displaying surface ulceration compared to 6 of 28 (21.4%) in conventional BCC (P < 0.0001). Admittedly, these statistical significances of depth and ulceration status may simply reflect the overall greater size of the GBCC group.
|Table 2: Histopathologic features of giant versus conventional basal cell carcinoma|
Click here to view
GBCCs more frequently displayed an aggressive subtype than conventional BCC [Figure 1] and [Figure 2]. Of conventional BCCs, 16 were classified as nonaggressive subtypes (nodular, superficial, or both nodular and superficial), while 12 tumors (43%) were classified as aggressive subtypes (infiltrative or nodular/infiltrative). In contrast, 7 GBCC tumors were classified as nonaggressive subtypes and 22 tumors were classified as aggressive subtypes (76%) (P = 0.016). Although necrosis was more often present in GBCC, seen in 68.9% of cases (20/29) versus 57.1% of conventional BCC (16/28), this trend was not statistically significant (P = 0.42) and likely simply reflects the greater size of GBCC.
|Figure 1: This conventional basal cell carcinoma is of the nodular subtype (Case 8) (H and E, ×100)|
Click here to view
|Figure 2: This giant basal cell carcinoma shows an infiltrative growth pattern, seen here invading as micronodules and infiltrative cords through atrophic skeletal muscle (Case 10) (H and E, ×100)|
Click here to view
Adnexal differentiation was completely absent in all cases of GBCC, while seven conventional BCCs (all nodular subtypes) showed evidence of adnexal differentiation [Figure 3] and [Figure 4], as evidenced by ductal, matrical, or trichilemmal differentiation (P = 0.0045). The frequency of squamous differentiation (squamatization) within tumor lobules was similar in GBCC (n = 20/29, 68.9%) and conventional BCC (n = 20/28, 71.4%) and was not significantly different between the groups (P = 1.00). Calcification was present in both tumor types at an approximately equal frequency (GBCC: n = 9/29, 31%, and conventional BCC: n = 10/28, 35.7%); this feature was not statistically different between the groups (P = 0.71).
|Figure 3: A conventional basal cell carcinoma, nodular and infiltrative subtypes, showing focal ductal differentiation within tumor nests (Case 1) (H and E, ×100)|
Click here to view
|Figure 4: This conventional basal cell carcinoma displays the focal presence of matrical differentiation as evidenced by trichohyaline granules (Case 34) (H and E, ×200)|
Click here to view
Lymphovascular invasion was not detected in any tumor. Perineural invasion was observed in 13.8% of GBCCs (4/29) and 10.7% (3/28) of conventional BCCs (P = 0.72). All cases exhibiting perineural invasion (excluding one case) were of the infiltrative subtype [Figure 5]. Although mitotic rate trended higher in GBCC (average: 18.6/mm 2, SD: 12.66, and range: 2–67) compared to conventional BCC (average: 15/mm 2, SD: 10.75, and range: 0–34), this parameter was not statistically significant (P = 0.25). Tumor cell pleomorphism [Figure 6] was observed more frequently in GBCC (n = 6, 20.6%) than in conventional BCC (n = 2, 7.1%), although this parameter was not statistically significant (P = 0.25).
|Figure 5: Tumor infiltration of a large caliber nerve is seen in this example of giant basal cell carcinoma (Case 18) (H and E, ×200)|
Click here to view
|Figure 6: Tumor cell pleomorphism was detected in a subset of tumors, as seen in this example of a giant basal cell carcinoma. Tumor cell necrosis is also present (Case 46) (H and E, ×400)|
Click here to view
Host response to tumor was also evaluated. The host response in each tumor was classified as absent, minimal, nonbrisk, or brisk. Absent, minimal, and nonbrisk inflammations were grouped together into a “low inflammation” category, which was compared to the incidence of brisk (high) inflammation. GBCCs tended to have high inflammation more often than did conventional BCCs, but this difference was not statistically significant (P = 0.3313). Interestingly, PC aggregates in association with the tumor (defined as >5 PCs clustered together in proximity to the tumor) were found to be significantly more common in GBCCs [Figure 7] and [Figure 8] than conventional BCCs. Twenty-eight of 29 GBCCs displayed PC clusters (96.55%) compared to 16 of 28 conventional BCCs (57.14%) (P = 0.0004).
|Figure 7: Plasma cells were more commonly seen as part of the host response in giant basal cell carcinomas (Case 5) (H and E, ×200)|
Click here to view
|Figure 8: This giant basal cell carcinoma demonstrates large numbers of plasma cells, including some that have intracytoplasmic Russell bodies (immunoglobulin inclusions) (Case 30) (H and E, ×400)|
Click here to view
| Discussion|| |
BCC is derived from its putative cell of origin, the basal cell, a type of keratinocyte located in the basal layer of the epidermis  and responsible for dividing and replenishing keratinocytes of the epidermis., However, many experts now regard the tumor to have its origin in follicular epithelium. Like most skin cancers, ultraviolet (UV) light plays an important role in the development of BCC, in this case by disrupting the Hedgehog signaling pathway. Derangement of this pathway results in unregulated cell proliferation that culminates as a cutaneous malignancy. Up to 85% of BCCs will contain mutations with genes involved in Hedgehog signaling, most commonly patched (PTCH) and smoothened (SMO). While UV light may induce somatic mutations in these genes and contribute to tumorigenesis, inherited mutations also play a role in tumor susceptibility. PTCH mutations are commonly found in patients with basal cell nevus (Gorlin) syndrome. Recent studies have also focused on examining other putative genetic and epigenetic alterations that would predispose certain individuals to the development of BCC. Single-nucleotide polymorphisms in a variety of genes have been shown to occur more frequently in patients diagnosed with BCC, including genes encoding proteins involved in DNA mismatch repair,,, telomere biology,, immune regulation, tumor progression, and skin pigmentation.,
GBCC, first recognized in 1951 by Eckhoff, is defined as a subtype of BCC that exceeds 5 cm in diameter. The largest series regarding GBCC to date is a 2009 meta-analysis reviewing 51 previously documented cases from the literature and focused on clinical features, outcomes, and basic histologic parameters (size and subtype). The largest series to date documenting histopathologic features of these unusual neoplasms is a recent case–control study of 13 GBCCs, which also examined the expression of neuromediators by immunohistochemistry as a mechanism to explain their large size. Most previous reports note that GBCCs commonly occur on the trunk as compared to conventional BCCs' predilection for the head/neck region.,, Our study did not corroborate this anatomic site distinction. In our series, similar to the recent study by Yazdani Abyaneh et al., GBCCs were seen with the highest incidence in the head/neck region, similar in incidence to conventional BCCs. This difference may reflect that ours is a retrospective study based on pathology reports from the archives predominantly from an academic hospital rather than a prospective, clinically oriented study. Our case material may be biased toward complicated surgical cases and could inadvertently exclude cases which were treated by other modalities.
The histological subtype of the tumor is said to play an important role in the development of GBCC, with some subtypes (infiltrative/morpheaform, micronodular, and basosquamous [previously metatypical]) being associated with a more aggressive course. Regardless of subtype, all GBCCs are capable of deep invasion with penetration into muscle or bone.,,,,,, Prior studies indicate that the majority of GBCC have an aggressive histologic subtype. Indeed, the majority of GBCC in our series had an infiltrative subtype, either alone or with a nodular component, supporting the findings of those previous studies. The infiltrative growth pattern was significantly more common than in conventional BCC, of which a minority showed infiltrative subtype.
Despite the fact that GBCC rarely metastasizes, the extent of local destruction represents a significant clinical management issue and often extensive morbidity for the patient. Surgical treatment may be a challenging endeavor in the head/neck region where many of these tumors arise., Vismodegib and more recently sonidegib, the Food and Drug Administration-approved sonic Hedgehog pathway inhibitors for unresectable or metastatic BCC, may be used to induce regression or shrink the tumor to a resectable size., Mohs microsurgery may be appropriate in cases where tissue sparing is imperative. Metastasis in GBCC has been reported, with bone marrow involvement leading to myelophthisic anemia; vismodegib would be the first-line therapy in cases of metastatic GBCC.
The cause for excessive growth in GBCCs is unknown. While genetic predispositions exist for the development of BCC of any type, no study to date has identified reproducible genetic susceptibility to the development of GBCC, likely due to the rarity of this tumor. The most widely accepted hypothesis suggests that GBCC is simply a product of neglect and allowed a longer clinical time course to reach maximum size, often over a period of 10–20 years. Support for this theory stems from an observation that this tumor is most commonly diagnosed in patients with lower socioeconomic status or physical disability, patient characteristics that may lead to delay in diagnosis and seeking treatment.,, Of note, in our study, we found that the average age of diagnosis of GBCC was similar to the age of diagnosis of conventional BCC. This series was designed only to examine the histologic parameters of GBCC and our data collection did not include information from the clinical records such as the duration of tumor growth prior to presentation for medical care. Therefore, while our observation regarding the age of presentation does not exclude a role for neglect in these large tumors, it also does not support the notion that patients with GBCC are simply waiting longer to present to a physician.
Other theories for the large size of GBCC exist. Northington et al. suggest that anogenital human papillomavirus (HPV) subtypes may be pathogenic in the development of some chronic GBCC, as those HPV subtypes have been isolated from these tumors in some studies. Yazdani Abyaneh et al. suggested that differing neuromodulator expression could account for size difference, but found that the expression of adrenocorticotropic hormone (ACTH), serotonin, β-endorphin, and met-enkephalin was similar in GBCC and conventional BCC. Other authors suggest that a weakened immune system plays an important role in tumorigenesis, and at least one study has found single-nucleotide polymorphisms in genes important in immune regulation in patients developing BCC (of any type, not specifically GBCC). Our study showed a nonsignificant trend toward more host inflammation in GBCC compared to conventional BCC; this finding would suggest that patients with GBCC can mount a host response, although our study was not designed to assess the functional capacity of the infiltrate. Local immune suppression may occur following chronic UV exposure, shifting predominant T-cell subsets in skin from a cytotoxic/effector phenotype to a regulatory phenotype, thereby promoting a microenvironment that is more suitable for tumor growth. BCC specifically has been shown in some studies to have a Th2-dominant host response with many T-regulatory cells already present. Cytotoxic T-cells within the peritumoral infiltrate are speculated to contribute to the restriction of tumor growth. Analysis of T-cell subsets within the host responses of GBCC and conventional BCC would be useful to more specifically characterize potential differences between the two different host immune microenvironments.
We observed a statistically significant increase in the presence of plasma cell (PC) aggregates within GBCC. PCs are infrequently commented upon in literature regarding cutaneous neoplasia and host responses. One study of 175 consecutive BCC found PC to be present in 65% of cases, with PC being more often seen in aggressive subtypes of BCC. PCs were also more often seen in ulcerated tumors and from male patients, both features of which were more common in our GBCC group. Whether PC aggregates indicate a yet undescribed role of humoral immunity in tumor microenvironment and host defense against BCC remains to be determined. However, a recent publication determined that melanomas with sheets or clusters of PCs had significantly worse survival than melanomas without PCs. Melanoma rich in PCs were seen statistically more often in older patients, ulcerated tumors, and tumors with high mitotic activity.
Innately difficult is determination of growth rate to assess whether GBCC grows more quickly than conventional BCC. Some literature suggests that larger tumors grow at a faster rate., In our study, GBCC was significantly deeper and more often ulcerated than its conventional counterpart, but these features may be accounted for simply by the greater size of GBCC rather than as a surrogate marker of rapid growth. Even their more frequent infiltrative subtype does not indicate a more rapid growth rate.
Our study identified several other notable, albeit nonsignificant, trends. Absolute data show that GBCC harbors a greater incidence of tumor cell atypia/pleomorphism (three times the rate of conventional BCC). Although histological grading is not routinely performed in BCC, high-grade cytologic atypia can influence prognosis in cancer of other organs. One study found nuclear pleomorphism predicted BCC recurrence in a univariate analysis, although this feature did not turn out to be an independent prognostic variable for recurrence upon multivariate analysis. Another interesting finding was absent adnexal differentiation in any of the 29 cases of GBCC, as opposed to 7 cases of conventional BCC that showed at least focal adnexal differentiation. Adnexal differentiation (including matrical, trichilemmal, or ductal) could correspond to a more “well-differentiated” tumor, a feature which, like nuclear grade, has prognostic meaning in cancer of other noncutaneous organs.
| Conclusions|| |
The conclusions drawn by our study are somewhat limited by its design. Clinical information such as physical status of patients, disease duration prior to diagnosis, and clinical course information such as prior administration of radiation or chemotherapy, recurrence, distant metastases, and mortality were not designed to be assessed by the current study. Addition of such information would be beneficial for a more complete analysis.
Although the process driving excessive growth displayed by GBCC is likely not entirely evaluable under light microscopy, there are certain aspects of our study suggesting future avenues for investigation, particularly with regard to host immune response. Excessive growth may be a consequence of different microenvironments these neoplasms are subjected to, features not readily assessable by light microscopy. Our observation of more frequent PC infiltrates within GBCC suggests an area worthy of further investigation, and further investigation of T-cell subsets within the host immune response may provide additional information regarding the complex relationship between host immune response and capacity for tumor growth and ultimate size.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, et al.
Giant basal cell carcinoma: Clinicopathological analysis of 51 cases and review of the literature. Anticancer Res 2009;29:2655-63.
Nasser N, Nasser Filho N, Trauczynski Neto B, Silva LM. Giant basal cell carcinoma. An Bras Dermatol 2012;87:469-71.
Randle HW, Roenigk RK, Brodland DG. Giant basal cell carcinoma (T3). Who is at risk? Cancer 1993;72:1624-30.
Anwar U, Al Ghazal SK, Ahmad M, Sharpe DT. Horrifying basal cell carcinoma forearm lesion leading to shoulder disarticulation. Plast Reconstr Surg 2006;117:6e-9e.
Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatol Surg 1996;22:255-61.
Welsch MJ, Troiani BM, Hale L, DelTondo J, Helm KF, Clarke LE, et al.
Basal cell carcinoma characteristics as predictors of depth of invasion. J Am Acad Dermatol 2012;67:47-53.
Zoccali G, Pajand R, Papa P, Orsini G, Lomartire N, Giuliani M, et al.
Giant basal cell carcinoma of the skin: Literature review and personal experience. J Eur Acad Dermatol Venereol 2012;26:942-52.
Schwartz RA, De Jager RL, Janniger CK, Lambert WC. Giant basal cell carcinoma with metastases and myelophthisic anemia. J Surg Oncol 1986;33:223-6.
Northington M, Tamburin L, Hamza S, Diwan H, Skelton H, Smith K, et al.
Giant basal cell carcinoma associated with human papillomaviruses infection. J Cutan Pathol 2004;31:174-8.
Sahl WJ. Highly malignant basal cell carcinoma: Report of a case and exposure of the “epithelioma” myth. Skin Cancer 1994;9:105-8.
Sahl WJ Jr., Snow SN, Levine NS. Giant basal cell carcinoma. Report of two cases and review of the literature. J Am Acad Dermatol 1994;30:856-9.
Tan E, Lin FP, Sheck LH, Salmon PJ, Ng SG. Growth of periocular basal cell carcinomas. Br J Dermatol 2015;172:1002-7.
Yazdani Abyaneh MA, Engel P, Slominski A, Ragsdale B, Agag R, Cramer D, et al.
Giant basal cell carcinomas express neuroactive mediators and show a high growth rate: A Case-control study and meta-analysis of etiopathogenic and prognostic factors. Am J Dermatopathol 2017;39:189-94.
Manstein CH, Manstein ME, Beidas OE. Giant basal cell carcinoma: 11-year follow-up and seven new cases. Plast Reconstr Surg 2011;128:1105-6.
Ruiz Salas V, Alegre M, Garcés JR, Puig L. Locally advanced and metastatic basal cell carcinoma: Molecular pathways, treatment options and new targeted therapies. Expert Rev Anticancer Ther 2014;14:741-9.
Chu SW, Biswas A. Basal cell carcinomas showing histological features generally associated with cutaneous adnexal neoplasms. J Cutan Pathol 2015;42:1049-62.
Canon PR, Robins P. Malignant tumors of the skin. In: McCarthy J, editor. Plastic Surgery. Philadelphia: W.B. Sanders Co.; 1990. p. 48.
Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al.
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016;48:398-406.
da Silva Calixto P, Lopes OS, Dos Santos Maia M, Herrero SST, Longui CA, Melo CGF, et al.
Single-nucleotide polymorphisms of the MSH2 and MLH1 genes, potential molecular markers for susceptibility to the development of basal cell carcinoma in the Brazilian population. Pathol Oncol Res 2017; Available from: https://doi.org/10.1007/s12253-017-0265-8
. June (e-pub), [Last accessed on 2018 Jan 27].
Lin Y, Chahal HS, Wu W, Cho HG, Ransohoff KJ, Song F, et al.
Association study of genetic variation in DNA repair pathway genes and risk of basal cell carcinoma. Int J Cancer 2017;141:952-7.
Sun Y, Liu Z, Liu Y, Li X. Polymorphisms in the nuclear excision repair gene ERCC2/XPD and susceptibility to cutaneous basal cell carcinoma. Int J Clin Exp Med 2015;8:10611-8.
Chahal HS, Wu W, Ransohoff KJ, Yang L, Hedlin H, Desai M, et al.
Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nat Commun 2016;7:12510.
Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, et al.
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol 2013;37:434-9.
Binstock M, Hafeez F, Metchnikoff C, Arron ST. Single-nucleotide polymorphisms in pigment genes and nonmelanoma skin cancer predisposition: A systematic review. Br J Dermatol 2014;171:713-21.
Beahrs OH, Henson DE, Hutter RV, Myers MH. American Joint Committee on Cancer Manual for Staging of Cancer. 3rd
ed. Philadelphia: J.B. Lippincott; 1988.
Eckhoff NL. Recurrent, multiple, and metastasizing basal-celled carcinomata. Br J Plast Surg 1951;3:264-81.
LeBoit P, Burg G, Weedon D, Sarasin A. World Health Organization classification of tumors. Pathology and Genetics of Skin Tumors. Lyon: IARC Press; 2006.
Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990;23:1118-26.
de Faria J. Basal cell carcinoma of the skin with areas of squamous cell carcinoma: A basosquamous cell carcinoma? J Clin Pathol 1985;38:1273-7.
Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr Med Res Opin 2015;31:743-56.
Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: A Systematic review and pooled analysis of interventional studies. JAMA Dermatol 2016;152:816-24.
Yu SH, Bordeaux JS, Baron ED. The immune system and skin cancer. Adv Exp Med Biol 2014;810:182-91.
Kaporis HG, Guttman-Yassky E, Lowes MA, Haider AS, Fuentes-Duculan J, Darabi K, et al.
Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 2007;127:2391-8.
Deng JS, Falo LD Jr., Kim B, Abell E. Cytotoxic T cells in basal cell carcinomas of skin. Am J Dermatopathol 1998;20:143-6.
Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: A histologic analysis. Am J Dermatopathol 2006;28:293-307.
Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, et al.
Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol 2016;29:347-58.
Dixon AY, Lee SH, McGregor DH. Factors predictive of recurrence of basal cell carcinoma. Am J Dermatopathol 1989;11:222-32.
Dixon AY, Lee SH, McGregor DH. Histologic features predictive of basal cell carcinoma recurrence: Results of a multivariate analysis. J Cutan Pathol 1993;20:137-42.
What is new?
- The histologic features of giant basal cell carcinoma reflect their large size, with increased overall size, tumor depth, and ulceration compared to conventional BCC.
- Tumor microenvironment may provide clues to giant BCC capacity for large size.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]
[Table 1], [Table 2]
| Article Access Statistics|
| Viewed||2669 |
| Printed||46 |
| Emailed||0 |
| PDF Downloaded||64 |
| Comments ||[Add] |